fashion -WSS

fashion

author：fashion 2025-09-29 23:12:41 - browse：42985

A sign of pharmaceutical company Bayer in front of a blossomed tree — coverage from STAT — INA FASSBENDER/AFP via Getty Images

More hopeful news on the menopause front: Bayer announced on Monday encouraging results in two Phase 3 trials for its non-hormonal drug candidate, elinzanetant, meant to treat hot flashes. The results follow the recent market launch of Veozah, Astellas Pharma’s groundbreaking non-hormonal treatment for hot flashes, which was approved by the U.S. Food and Drug Administration last spring and received approval in the U.K., under the name Veozah, in December.

Elinzanetant is a neurokinin-1 and 3 receptor antagonist, and works by calming down the estrogen receptors in the brain that become hyperactive around menopause, causing hot flashes. The drug, a pill administered once a day, was shown to reduce both the frequency and intensity of hot flashes, and also met the secondary endpoints for improving sleep and quality of life, according to JoAnn Pinkerton, professor of obstetrics and gynecology and director of the Midlife Health at UVA Health, who is a clinical investigator for Bayer’s drug candidate.

Pinkerton said she was excited to see the broader quality of life improvements through elinzanetant: “Women have more than just hot flashes — it’s actually more about hot flushes, sweats, fatigue, lack of sleep and some of the mood changes that go on during [menopause].”

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： How one medical school became remarkably diverse
Next article： Readout LOUD podcast: Vertex data, Aduhelm, & Woodcock retires

WSS

等到积累多了量够了，在缺乏灵感时还是可以帮助你想到一个相对靠谱的方案，如果能够加上好的落地执行（往往绝大部分人是不会执行的），相信会做出一个创意不错的运营案例。

Vertigo drug brings hope for rare neuron disorder, Niemann

Australia's humpback populations rebound raising hopes of marine scientists

These geoengineering technologies could help combat the climate crisis, scientists say

Why is France rioting? What to know about the fatal police shooting of Nahel M

SAMSHA loosens regulations on methadone treatment centers

hotspot

fashion

explore

Heart attack and stroke risk calculators need revising

Vertex non

Affirmative action in medical school literally saved lives

Pfizer's Covid pill remains 89% effective in final analysis, company says

FDA approval of Sarepta Duchenne genetic therapy gives me hope

The lessons of Aduhelm, an Alzheimer's drug that was not to be

In age of alternative facts, a scholarly course on calling out crap

Can food be medicine? And other questions about a new push

Hepatitis C has a cure — but many Americans still lack access to it

Listen: Biogen's messy board & Laronde's data problem

explore

These geoengineering technologies could help combat the climate crisis, scientists say

Australia's humpback populations rebound raising hopes of marine scientists

4 killed, 7 hurt in mass shooting at July 4 block party in Louisiana; no arrests made

Readout LOUD podcast: Vertex data, Aduhelm, & Woodcock retires

Duchenne patients, backed by ‘dark money’ group, to debate drug prices

Listen: PBM conflicts, RSV vaccines, & the future of flu season

focus

explore

hotspot

focus